PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11455973 |
| CHEMBL ID | 4297321 |
| SCHEMBL ID | 367963 |
| MeSH ID | M0512973 |
| Synonym |
|---|
| pr-104 |
| benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5- dinitro-n-(2-(phosphonooxy)ethyl)- |
| 851627-62-8 |
| pr 104 |
| v16d2zt7dt , |
| unii-v16d2zt7dt |
| 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate |
| ((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)-carbonyl)anilino)ethyl methanesulfonate |
| ((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)-carbonyl)anilino)ethyl methanesulphonate |
| pr 104 [who-dd] |
| AKOS022174966 |
| SCHEMBL367963 |
| 2-((2-bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate |
| pr-104/104a |
| J-507569 |
| pr104 |
| DB05968 |
| Q25327019 |
| CHEMBL4297321 |
| DTXSID001005607 |
| 2-[(2-bromoethyl){2-[(methanesulfonyl)oxy]ethyl}amino]-3,5-dinitro-n-[2-(phosphonooxy)ethyl]benzene-1-carboximidic acid |
| 2-[n-(2-bromoethyl)-2,4-dinitro-6-(2-phosphonooxyethylcarbamoyl)anilino]ethyl methanesulfonate |
| CS-0006324 |
| c14h20brn4o12ps |
| HY-16405 |
| AT37732 |
| AKOS040755172 |
PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two. PR-104 is a bioreductive pre-prodrug given in combination with gemcitabine or docetAXel in patients with advanced solid tumours.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 2.04 |
| "PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with gemcitabine 800 mg/m2 on days one and eight, of a 21-day treatment cycle." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 3.26 |
| " The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 2.2 |
| " A recommended dose was identified for phase II trials of PR-104 of 770 mg/m2 combined with docetaxel 60 to 75 mg/m2 both given on day one of a 21-day treatment cycle supported by prophylactic G-CSF (NCT00459836)." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 2.07 |
PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship. PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course of treatment with fractionated radiotherapy or haematopoietic stem cell support.
| Excerpt | Relevance | Reference |
|---|---|---|
| " At 270 mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship." | ( Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Carol, H; Gorlick, R; Gu, Y; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Phelps, D; Reynolds, CP; Smith, MA; Wilson, WR; Wozniak, AW, 2011) | 0.9 |
| " PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course of treatment with fractionated radiotherapy or haematopoietic stem cell support, as its duration of dosing is restricted by delayed-onset and protracted thrombocytopenia." | ( A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. Amies, K; Gu, Y; Hill, A; Jameson, MB; McKeage, MJ; Melink, TJ; Wilson, WR, 2011) | 1.61 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (63.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (25.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (70.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||